nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Topoisomerase Inhibitors—Teniposide—lymphatic system cancer	0.365	0.569	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Mitoxantrone—lymphatic system cancer	0.277	0.431	CiPCiCtD
Doxorubicin—RALBP1—Vincristine—lymphatic system cancer	0.0442	0.155	CbGbCtD
Doxorubicin—ABCC6—Teniposide—lymphatic system cancer	0.0442	0.155	CbGbCtD
Doxorubicin—ABCC10—Cytarabine—lymphatic system cancer	0.0342	0.12	CbGbCtD
Doxorubicin—TOP2A—Teniposide—lymphatic system cancer	0.0235	0.0823	CbGbCtD
Doxorubicin—TOP2A—Mitoxantrone—lymphatic system cancer	0.0164	0.0576	CbGbCtD
Doxorubicin—ABCC10—Vincristine—lymphatic system cancer	0.0162	0.0569	CbGbCtD
Doxorubicin—CYP1B1—Mitoxantrone—lymphatic system cancer	0.0128	0.0449	CbGbCtD
Doxorubicin—ABCC3—Vincristine—lymphatic system cancer	0.0102	0.0358	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—lymphatic system cancer	0.00983	0.0344	CbGbCtD
Doxorubicin—ABCC1—Mitoxantrone—lymphatic system cancer	0.00911	0.0319	CbGbCtD
Doxorubicin—ABCB11—Vincristine—lymphatic system cancer	0.00882	0.0309	CbGbCtD
Doxorubicin—ABCG2—Teniposide—lymphatic system cancer	0.00872	0.0305	CbGbCtD
Doxorubicin—ABCC1—Vincristine—lymphatic system cancer	0.00627	0.022	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—lymphatic system cancer	0.00618	0.0216	CbGbCtD
Doxorubicin—ABCG2—Mitoxantrone—lymphatic system cancer	0.0061	0.0213	CbGbCtD
Doxorubicin—ABCC2—Vincristine—lymphatic system cancer	0.00464	0.0163	CbGbCtD
Doxorubicin—ABCG2—Vincristine—lymphatic system cancer	0.0042	0.0147	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—lymphatic system cancer	0.0038	0.0133	CbGbCtD
Doxorubicin—ABCC2—Methotrexate—lymphatic system cancer	0.00281	0.00984	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—lymphatic system cancer	0.00254	0.0089	CbGbCtD
Doxorubicin—ABCB1—Mitoxantrone—lymphatic system cancer	0.0022	0.0077	CbGbCtD
Doxorubicin—CYP3A4—Cytarabine—lymphatic system cancer	0.00191	0.00669	CbGbCtD
Doxorubicin—CYP3A4—Teniposide—lymphatic system cancer	0.00188	0.00659	CbGbCtD
Doxorubicin—ABCB1—Vincristine—lymphatic system cancer	0.00151	0.0053	CbGbCtD
Doxorubicin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00132	0.00461	CbGbCtD
Doxorubicin—ABCB1—Methotrexate—lymphatic system cancer	0.000916	0.00321	CbGbCtD
Doxorubicin—CYP3A4—Vincristine—lymphatic system cancer	0.000906	0.00317	CbGbCtD
Doxorubicin—ABCC6—Podofilox—Teniposide—lymphatic system cancer	0.000306	0.164	CbGdCrCtD
Doxorubicin—AKR1C3—Podofilox—Teniposide—lymphatic system cancer	0.000267	0.143	CbGdCrCtD
Doxorubicin—AURKA—Etoposide—Teniposide—lymphatic system cancer	0.00019	0.102	CbGdCrCtD
Doxorubicin—AKR1C3—Vinblastine—Vincristine—lymphatic system cancer	0.000109	0.0585	CbGdCrCtD
Doxorubicin—CBR3—Gemcitabine—Cytarabine—lymphatic system cancer	0.0001	0.0536	CbGdCrCtD
Doxorubicin—TOP2A—Etoposide—Teniposide—lymphatic system cancer	7.26e-05	0.0389	CbGdCrCtD
Doxorubicin—CBR3—Azacitidine—Fludarabine—lymphatic system cancer	6.98e-05	0.0374	CbGdCrCtD
Doxorubicin—CBR3—Azacitidine—Cytarabine—lymphatic system cancer	6.6e-05	0.0353	CbGdCrCtD
Doxorubicin—AURKA—Cladribine—Fludarabine—lymphatic system cancer	6.53e-05	0.0349	CbGdCrCtD
Doxorubicin—AURKA—Clofarabine—Fludarabine—lymphatic system cancer	6.03e-05	0.0323	CbGdCrCtD
Doxorubicin—AURKA—Clofarabine—Cytarabine—lymphatic system cancer	5.7e-05	0.0305	CbGdCrCtD
Doxorubicin—TOP2A—Podofilox—Teniposide—lymphatic system cancer	5.54e-05	0.0296	CbGdCrCtD
Doxorubicin—AURKA—Gemcitabine—Cytarabine—lymphatic system cancer	5.28e-05	0.0283	CbGdCrCtD
Doxorubicin—TOP2A—Vindesine—Vincristine—lymphatic system cancer	5.22e-05	0.028	CbGdCrCtD
Doxorubicin—CBR1—Azacitidine—Fludarabine—lymphatic system cancer	5.18e-05	0.0277	CbGdCrCtD
Doxorubicin—AURKA—Cytarabine—Fludarabine—lymphatic system cancer	5.13e-05	0.0275	CbGdCrCtD
Doxorubicin—CBR1—Azacitidine—Cytarabine—lymphatic system cancer	4.89e-05	0.0262	CbGdCrCtD
Doxorubicin—Dermatitis—Teniposide—lymphatic system cancer	4.04e-05	0.00057	CcSEcCtD
Doxorubicin—Dysgeusia—Mitoxantrone—lymphatic system cancer	4.02e-05	0.000568	CcSEcCtD
Doxorubicin—Headache—Teniposide—lymphatic system cancer	4.02e-05	0.000567	CcSEcCtD
Doxorubicin—Pruritus—Fludarabine—lymphatic system cancer	3.99e-05	0.000563	CcSEcCtD
Doxorubicin—Lymphadenopathy—Methotrexate—lymphatic system cancer	3.98e-05	0.000562	CcSEcCtD
Doxorubicin—Back pain—Mitoxantrone—lymphatic system cancer	3.97e-05	0.000561	CcSEcCtD
Doxorubicin—Leukopenia—Carmustine—lymphatic system cancer	3.96e-05	0.000558	CcSEcCtD
Doxorubicin—Anorexia—Bleomycin—lymphatic system cancer	3.94e-05	0.000556	CcSEcCtD
Doxorubicin—Thrombophlebitis—Methotrexate—lymphatic system cancer	3.93e-05	0.000554	CcSEcCtD
Doxorubicin—Diabetes mellitus—Methotrexate—lymphatic system cancer	3.91e-05	0.000551	CcSEcCtD
Doxorubicin—Anaemia—Vincristine—lymphatic system cancer	3.9e-05	0.00055	CcSEcCtD
Doxorubicin—Agitation—Vincristine—lymphatic system cancer	3.88e-05	0.000547	CcSEcCtD
Doxorubicin—Vision blurred—Mitoxantrone—lymphatic system cancer	3.87e-05	0.000546	CcSEcCtD
Doxorubicin—Photosensitivity—Methotrexate—lymphatic system cancer	3.87e-05	0.000546	CcSEcCtD
Doxorubicin—Hypotension—Bleomycin—lymphatic system cancer	3.86e-05	0.000545	CcSEcCtD
Doxorubicin—Diarrhoea—Fludarabine—lymphatic system cancer	3.86e-05	0.000544	CcSEcCtD
Doxorubicin—Convulsion—Carmustine—lymphatic system cancer	3.83e-05	0.00054	CcSEcCtD
Doxorubicin—Hypertension—Carmustine—lymphatic system cancer	3.82e-05	0.000538	CcSEcCtD
Doxorubicin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	3.81e-05	0.000538	CcSEcCtD
Doxorubicin—Nausea—Teniposide—lymphatic system cancer	3.81e-05	0.000537	CcSEcCtD
Doxorubicin—Anaemia—Mitoxantrone—lymphatic system cancer	3.8e-05	0.000536	CcSEcCtD
Doxorubicin—Vertigo—Vincristine—lymphatic system cancer	3.79e-05	0.000535	CcSEcCtD
Doxorubicin—Hepatic failure—Methotrexate—lymphatic system cancer	3.78e-05	0.000534	CcSEcCtD
Doxorubicin—Leukopenia—Vincristine—lymphatic system cancer	3.78e-05	0.000533	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	3.76e-05	0.000531	CcSEcCtD
Doxorubicin—Myalgia—Carmustine—lymphatic system cancer	3.76e-05	0.000531	CcSEcCtD
Doxorubicin—Chest pain—Carmustine—lymphatic system cancer	3.76e-05	0.000531	CcSEcCtD
Doxorubicin—Anxiety—Carmustine—lymphatic system cancer	3.75e-05	0.000529	CcSEcCtD
Doxorubicin—Paraesthesia—Bleomycin—lymphatic system cancer	3.71e-05	0.000523	CcSEcCtD
Doxorubicin—Malaise—Mitoxantrone—lymphatic system cancer	3.71e-05	0.000523	CcSEcCtD
Doxorubicin—Dyspnoea—Bleomycin—lymphatic system cancer	3.68e-05	0.00052	CcSEcCtD
Doxorubicin—Renal failure acute—Methotrexate—lymphatic system cancer	3.68e-05	0.000519	CcSEcCtD
Doxorubicin—Leukopenia—Mitoxantrone—lymphatic system cancer	3.68e-05	0.000519	CcSEcCtD
Doxorubicin—Convulsion—Vincristine—lymphatic system cancer	3.66e-05	0.000516	CcSEcCtD
Doxorubicin—Hypertension—Vincristine—lymphatic system cancer	3.64e-05	0.000514	CcSEcCtD
Doxorubicin—Confusional state—Carmustine—lymphatic system cancer	3.64e-05	0.000513	CcSEcCtD
Doxorubicin—Oedema—Carmustine—lymphatic system cancer	3.61e-05	0.000509	CcSEcCtD
Doxorubicin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	3.6e-05	0.000508	CcSEcCtD
Doxorubicin—Decreased appetite—Bleomycin—lymphatic system cancer	3.59e-05	0.000507	CcSEcCtD
Doxorubicin—Myalgia—Vincristine—lymphatic system cancer	3.59e-05	0.000507	CcSEcCtD
Doxorubicin—Cough—Mitoxantrone—lymphatic system cancer	3.59e-05	0.000506	CcSEcCtD
Doxorubicin—Infection—Carmustine—lymphatic system cancer	3.58e-05	0.000506	CcSEcCtD
Doxorubicin—Vomiting—Fludarabine—lymphatic system cancer	3.58e-05	0.000506	CcSEcCtD
Doxorubicin—Convulsion—Mitoxantrone—lymphatic system cancer	3.56e-05	0.000502	CcSEcCtD
Doxorubicin—Rash—Fludarabine—lymphatic system cancer	3.55e-05	0.000501	CcSEcCtD
Doxorubicin—Dermatitis—Fludarabine—lymphatic system cancer	3.55e-05	0.000501	CcSEcCtD
Doxorubicin—Hypertension—Mitoxantrone—lymphatic system cancer	3.55e-05	0.0005	CcSEcCtD
Doxorubicin—Pain—Bleomycin—lymphatic system cancer	3.53e-05	0.000499	CcSEcCtD
Doxorubicin—Thrombocytopenia—Carmustine—lymphatic system cancer	3.53e-05	0.000498	CcSEcCtD
Doxorubicin—Headache—Fludarabine—lymphatic system cancer	3.53e-05	0.000498	CcSEcCtD
Doxorubicin—Tachycardia—Carmustine—lymphatic system cancer	3.52e-05	0.000497	CcSEcCtD
Doxorubicin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	3.51e-05	0.000495	CcSEcCtD
Doxorubicin—Arthralgia—Mitoxantrone—lymphatic system cancer	3.5e-05	0.000494	CcSEcCtD
Doxorubicin—Chest pain—Mitoxantrone—lymphatic system cancer	3.5e-05	0.000494	CcSEcCtD
Doxorubicin—Myalgia—Mitoxantrone—lymphatic system cancer	3.5e-05	0.000494	CcSEcCtD
Doxorubicin—Anxiety—Mitoxantrone—lymphatic system cancer	3.49e-05	0.000492	CcSEcCtD
Doxorubicin—Lethargy—Methotrexate—lymphatic system cancer	3.47e-05	0.000489	CcSEcCtD
Doxorubicin—Cerebrovascular accident—Methotrexate—lymphatic system cancer	3.47e-05	0.000489	CcSEcCtD
Doxorubicin—Discomfort—Mitoxantrone—lymphatic system cancer	3.46e-05	0.000488	CcSEcCtD
Doxorubicin—Anaphylactic shock—Vincristine—lymphatic system cancer	3.44e-05	0.000486	CcSEcCtD
Doxorubicin—Oedema—Vincristine—lymphatic system cancer	3.44e-05	0.000486	CcSEcCtD
Doxorubicin—Anorexia—Carmustine—lymphatic system cancer	3.44e-05	0.000485	CcSEcCtD
Doxorubicin—Infection—Vincristine—lymphatic system cancer	3.42e-05	0.000483	CcSEcCtD
Doxorubicin—Feeling abnormal—Bleomycin—lymphatic system cancer	3.41e-05	0.00048	CcSEcCtD
Doxorubicin—Osteoarthritis—Methotrexate—lymphatic system cancer	3.4e-05	0.00048	CcSEcCtD
Doxorubicin—Confusional state—Mitoxantrone—lymphatic system cancer	3.38e-05	0.000477	CcSEcCtD
Doxorubicin—Nervous system disorder—Vincristine—lymphatic system cancer	3.38e-05	0.000476	CcSEcCtD
Doxorubicin—Thrombocytopenia—Vincristine—lymphatic system cancer	3.37e-05	0.000476	CcSEcCtD
Doxorubicin—Hypotension—Carmustine—lymphatic system cancer	3.37e-05	0.000476	CcSEcCtD
Doxorubicin—Oedema—Mitoxantrone—lymphatic system cancer	3.35e-05	0.000473	CcSEcCtD
Doxorubicin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	3.35e-05	0.000473	CcSEcCtD
Doxorubicin—Nausea—Fludarabine—lymphatic system cancer	3.35e-05	0.000472	CcSEcCtD
Doxorubicin—Infection—Mitoxantrone—lymphatic system cancer	3.33e-05	0.00047	CcSEcCtD
Doxorubicin—Hyperhidrosis—Vincristine—lymphatic system cancer	3.33e-05	0.00047	CcSEcCtD
Doxorubicin—Shock—Mitoxantrone—lymphatic system cancer	3.3e-05	0.000465	CcSEcCtD
Doxorubicin—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	3.3e-05	0.0176	CbGdCrCtD
Doxorubicin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.29e-05	0.000464	CcSEcCtD
Doxorubicin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.28e-05	0.000463	CcSEcCtD
Doxorubicin—Urticaria—Bleomycin—lymphatic system cancer	3.28e-05	0.000463	CcSEcCtD
Doxorubicin—Anorexia—Vincristine—lymphatic system cancer	3.28e-05	0.000463	CcSEcCtD
Doxorubicin—Tachycardia—Mitoxantrone—lymphatic system cancer	3.27e-05	0.000462	CcSEcCtD
Doxorubicin—Body temperature increased—Bleomycin—lymphatic system cancer	3.27e-05	0.000461	CcSEcCtD
Doxorubicin—Insomnia—Carmustine—lymphatic system cancer	3.26e-05	0.00046	CcSEcCtD
Doxorubicin—Skin disorder—Mitoxantrone—lymphatic system cancer	3.26e-05	0.00046	CcSEcCtD
Doxorubicin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	3.24e-05	0.000457	CcSEcCtD
Doxorubicin—Paraesthesia—Carmustine—lymphatic system cancer	3.24e-05	0.000457	CcSEcCtD
Doxorubicin—Mood swings—Methotrexate—lymphatic system cancer	3.22e-05	0.000454	CcSEcCtD
Doxorubicin—Hypotension—Vincristine—lymphatic system cancer	3.22e-05	0.000454	CcSEcCtD
Doxorubicin—Dyspnoea—Carmustine—lymphatic system cancer	3.22e-05	0.000454	CcSEcCtD
Doxorubicin—Somnolence—Carmustine—lymphatic system cancer	3.21e-05	0.000452	CcSEcCtD
Doxorubicin—Anorexia—Mitoxantrone—lymphatic system cancer	3.2e-05	0.000451	CcSEcCtD
Doxorubicin—Ataxia—Methotrexate—lymphatic system cancer	3.2e-05	0.000451	CcSEcCtD
Doxorubicin—Liver function test abnormal—Methotrexate—lymphatic system cancer	3.14e-05	0.000443	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.14e-05	0.000443	CcSEcCtD
Doxorubicin—Decreased appetite—Carmustine—lymphatic system cancer	3.14e-05	0.000442	CcSEcCtD
Doxorubicin—Hypotension—Mitoxantrone—lymphatic system cancer	3.13e-05	0.000442	CcSEcCtD
Doxorubicin—Insomnia—Vincristine—lymphatic system cancer	3.11e-05	0.000439	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.11e-05	0.000439	CcSEcCtD
Doxorubicin—Paraesthesia—Vincristine—lymphatic system cancer	3.09e-05	0.000436	CcSEcCtD
Doxorubicin—Pain—Carmustine—lymphatic system cancer	3.08e-05	0.000435	CcSEcCtD
Doxorubicin—Constipation—Carmustine—lymphatic system cancer	3.08e-05	0.000435	CcSEcCtD
Doxorubicin—Breast disorder—Methotrexate—lymphatic system cancer	3.07e-05	0.000433	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	3.06e-05	0.000432	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.06e-05	0.000431	CcSEcCtD
Doxorubicin—Hypersensitivity—Bleomycin—lymphatic system cancer	3.04e-05	0.00043	CcSEcCtD
Doxorubicin—Paraesthesia—Mitoxantrone—lymphatic system cancer	3.01e-05	0.000425	CcSEcCtD
Doxorubicin—Decreased appetite—Vincristine—lymphatic system cancer	2.99e-05	0.000422	CcSEcCtD
Doxorubicin—Dyspnoea—Mitoxantrone—lymphatic system cancer	2.99e-05	0.000422	CcSEcCtD
Doxorubicin—Somnolence—Mitoxantrone—lymphatic system cancer	2.98e-05	0.000421	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	2.97e-05	0.000419	CcSEcCtD
Doxorubicin—Feeling abnormal—Carmustine—lymphatic system cancer	2.97e-05	0.000419	CcSEcCtD
Doxorubicin—Fatigue—Vincristine—lymphatic system cancer	2.97e-05	0.000419	CcSEcCtD
Doxorubicin—Asthenia—Bleomycin—lymphatic system cancer	2.96e-05	0.000418	CcSEcCtD
Doxorubicin—Dyspepsia—Mitoxantrone—lymphatic system cancer	2.95e-05	0.000416	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Carmustine—lymphatic system cancer	2.95e-05	0.000416	CcSEcCtD
Doxorubicin—Constipation—Vincristine—lymphatic system cancer	2.94e-05	0.000415	CcSEcCtD
Doxorubicin—Pain—Vincristine—lymphatic system cancer	2.94e-05	0.000415	CcSEcCtD
Doxorubicin—Asthma—Methotrexate—lymphatic system cancer	2.94e-05	0.000414	CcSEcCtD
Doxorubicin—Pruritus—Bleomycin—lymphatic system cancer	2.92e-05	0.000412	CcSEcCtD
Doxorubicin—Decreased appetite—Mitoxantrone—lymphatic system cancer	2.92e-05	0.000411	CcSEcCtD
Doxorubicin—Eosinophilia—Methotrexate—lymphatic system cancer	2.91e-05	0.00041	CcSEcCtD
Doxorubicin—Fatigue—Mitoxantrone—lymphatic system cancer	2.89e-05	0.000408	CcSEcCtD
Doxorubicin—Pancreatitis—Methotrexate—lymphatic system cancer	2.88e-05	0.000406	CcSEcCtD
Doxorubicin—Constipation—Mitoxantrone—lymphatic system cancer	2.87e-05	0.000405	CcSEcCtD
Doxorubicin—Pain—Mitoxantrone—lymphatic system cancer	2.87e-05	0.000405	CcSEcCtD
Doxorubicin—Abdominal pain—Carmustine—lymphatic system cancer	2.85e-05	0.000402	CcSEcCtD
Doxorubicin—Body temperature increased—Carmustine—lymphatic system cancer	2.85e-05	0.000402	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Vincristine—lymphatic system cancer	2.82e-05	0.000397	CcSEcCtD
Doxorubicin—Pancytopenia—Methotrexate—lymphatic system cancer	2.79e-05	0.000394	CcSEcCtD
Doxorubicin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	2.76e-05	0.00039	CcSEcCtD
Doxorubicin—Dysuria—Methotrexate—lymphatic system cancer	2.75e-05	0.000388	CcSEcCtD
Doxorubicin—Neutropenia—Methotrexate—lymphatic system cancer	2.75e-05	0.000388	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	2.74e-05	0.000387	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	2.73e-05	0.000385	CcSEcCtD
Doxorubicin—Abdominal pain—Vincristine—lymphatic system cancer	2.72e-05	0.000384	CcSEcCtD
Doxorubicin—Body temperature increased—Vincristine—lymphatic system cancer	2.72e-05	0.000384	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	2.68e-05	0.000378	CcSEcCtD
Doxorubicin—Urticaria—Mitoxantrone—lymphatic system cancer	2.66e-05	0.000376	CcSEcCtD
Doxorubicin—Hypersensitivity—Carmustine—lymphatic system cancer	2.66e-05	0.000375	CcSEcCtD
Doxorubicin—Abdominal pain—Mitoxantrone—lymphatic system cancer	2.65e-05	0.000374	CcSEcCtD
Doxorubicin—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.65e-05	0.000374	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—lymphatic system cancer	2.63e-05	0.000372	CcSEcCtD
Doxorubicin—Vomiting—Bleomycin—lymphatic system cancer	2.63e-05	0.000371	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—lymphatic system cancer	2.62e-05	0.00037	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—lymphatic system cancer	2.62e-05	0.00037	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—lymphatic system cancer	2.62e-05	0.00037	CcSEcCtD
Doxorubicin—Rash—Bleomycin—lymphatic system cancer	2.61e-05	0.000368	CcSEcCtD
Doxorubicin—Dermatitis—Bleomycin—lymphatic system cancer	2.6e-05	0.000367	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	2.6e-05	0.000366	CcSEcCtD
Doxorubicin—Asthenia—Carmustine—lymphatic system cancer	2.59e-05	0.000365	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—lymphatic system cancer	2.58e-05	0.000363	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—lymphatic system cancer	2.55e-05	0.00036	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—lymphatic system cancer	2.55e-05	0.000359	CcSEcCtD
Doxorubicin—Hypersensitivity—Vincristine—lymphatic system cancer	2.54e-05	0.000358	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—lymphatic system cancer	2.51e-05	0.000354	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—lymphatic system cancer	2.5e-05	0.000352	CcSEcCtD
Doxorubicin—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	2.49e-05	0.0133	CbGdCrCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.48e-05	0.00035	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—lymphatic system cancer	2.47e-05	0.000349	CcSEcCtD
Doxorubicin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.47e-05	0.000349	CcSEcCtD
Doxorubicin—Asthenia—Vincristine—lymphatic system cancer	2.47e-05	0.000349	CcSEcCtD
Doxorubicin—Diarrhoea—Carmustine—lymphatic system cancer	2.47e-05	0.000348	CcSEcCtD
Doxorubicin—Nausea—Bleomycin—lymphatic system cancer	2.45e-05	0.000346	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—lymphatic system cancer	2.44e-05	0.000345	CcSEcCtD
Doxorubicin—Asthenia—Mitoxantrone—lymphatic system cancer	2.41e-05	0.000339	CcSEcCtD
Doxorubicin—Dizziness—Carmustine—lymphatic system cancer	2.39e-05	0.000337	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—lymphatic system cancer	2.36e-05	0.000333	CcSEcCtD
Doxorubicin—Diarrhoea—Vincristine—lymphatic system cancer	2.36e-05	0.000332	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—lymphatic system cancer	2.35e-05	0.000332	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—lymphatic system cancer	2.35e-05	0.000332	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—lymphatic system cancer	2.33e-05	0.000329	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.32e-05	0.000328	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—lymphatic system cancer	2.31e-05	0.000325	CcSEcCtD
Doxorubicin—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	2.31e-05	0.0123	CbGdCrCtD
Doxorubicin—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.29e-05	0.000324	CcSEcCtD
Doxorubicin—Vomiting—Carmustine—lymphatic system cancer	2.29e-05	0.000324	CcSEcCtD
Doxorubicin—Dizziness—Vincristine—lymphatic system cancer	2.28e-05	0.000321	CcSEcCtD
Doxorubicin—Rash—Carmustine—lymphatic system cancer	2.27e-05	0.000321	CcSEcCtD
Doxorubicin—Dermatitis—Carmustine—lymphatic system cancer	2.27e-05	0.000321	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—lymphatic system cancer	2.27e-05	0.00032	CcSEcCtD
Doxorubicin—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	2.27e-05	0.0121	CbGdCrCtD
Doxorubicin—Headache—Carmustine—lymphatic system cancer	2.26e-05	0.000319	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—lymphatic system cancer	2.22e-05	0.000314	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—lymphatic system cancer	2.2e-05	0.00031	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—lymphatic system cancer	2.19e-05	0.000309	CcSEcCtD
Doxorubicin—Vomiting—Vincristine—lymphatic system cancer	2.19e-05	0.000309	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—lymphatic system cancer	2.18e-05	0.000308	CcSEcCtD
Doxorubicin—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	2.18e-05	0.0117	CbGdCrCtD
Doxorubicin—Rash—Vincristine—lymphatic system cancer	2.17e-05	0.000306	CcSEcCtD
Doxorubicin—Dermatitis—Vincristine—lymphatic system cancer	2.17e-05	0.000306	CcSEcCtD
Doxorubicin—Headache—Vincristine—lymphatic system cancer	2.16e-05	0.000304	CcSEcCtD
Doxorubicin—Nausea—Carmustine—lymphatic system cancer	2.14e-05	0.000302	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—lymphatic system cancer	2.13e-05	0.000301	CcSEcCtD
Doxorubicin—Vomiting—Mitoxantrone—lymphatic system cancer	2.13e-05	0.000301	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—lymphatic system cancer	2.12e-05	0.0003	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.12e-05	0.000299	CcSEcCtD
Doxorubicin—Rash—Mitoxantrone—lymphatic system cancer	2.11e-05	0.000298	CcSEcCtD
Doxorubicin—Dermatitis—Mitoxantrone—lymphatic system cancer	2.11e-05	0.000298	CcSEcCtD
Doxorubicin—Chills—Methotrexate—lymphatic system cancer	2.11e-05	0.000298	CcSEcCtD
Doxorubicin—Headache—Mitoxantrone—lymphatic system cancer	2.1e-05	0.000296	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—lymphatic system cancer	2.08e-05	0.000293	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—lymphatic system cancer	2.06e-05	0.000291	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—lymphatic system cancer	2.05e-05	0.000289	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—lymphatic system cancer	2.05e-05	0.000289	CcSEcCtD
Doxorubicin—Nausea—Vincristine—lymphatic system cancer	2.05e-05	0.000289	CcSEcCtD
Doxorubicin—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	2.02e-05	0.0108	CbGdCrCtD
Doxorubicin—Dysgeusia—Methotrexate—lymphatic system cancer	2e-05	0.000283	CcSEcCtD
Doxorubicin—Nausea—Mitoxantrone—lymphatic system cancer	1.99e-05	0.000281	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—lymphatic system cancer	1.98e-05	0.000279	CcSEcCtD
Doxorubicin—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	1.96e-05	0.0105	CbGdCrCtD
Doxorubicin—Vision blurred—Methotrexate—lymphatic system cancer	1.93e-05	0.000272	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—lymphatic system cancer	1.9e-05	0.000268	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—lymphatic system cancer	1.89e-05	0.000267	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—lymphatic system cancer	1.85e-05	0.00026	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—lymphatic system cancer	1.84e-05	0.000259	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—lymphatic system cancer	1.83e-05	0.000259	CcSEcCtD
Doxorubicin—Cough—Methotrexate—lymphatic system cancer	1.79e-05	0.000252	CcSEcCtD
Doxorubicin—Convulsion—Methotrexate—lymphatic system cancer	1.77e-05	0.00025	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—lymphatic system cancer	1.74e-05	0.000246	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—lymphatic system cancer	1.74e-05	0.000246	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—lymphatic system cancer	1.74e-05	0.000246	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	1.73e-05	0.000244	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—lymphatic system cancer	1.72e-05	0.000243	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—lymphatic system cancer	1.68e-05	0.000238	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.67e-05	0.000236	CcSEcCtD
Doxorubicin—Infection—Methotrexate—lymphatic system cancer	1.66e-05	0.000234	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—lymphatic system cancer	1.64e-05	0.000231	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.64e-05	0.000231	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—lymphatic system cancer	1.62e-05	0.000229	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—lymphatic system cancer	1.62e-05	0.000228	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—lymphatic system cancer	1.59e-05	0.000225	CcSEcCtD
Doxorubicin—Hypotension—Methotrexate—lymphatic system cancer	1.56e-05	0.00022	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.52e-05	0.000215	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—lymphatic system cancer	1.51e-05	0.000213	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—lymphatic system cancer	1.5e-05	0.000212	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—lymphatic system cancer	1.49e-05	0.00021	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—lymphatic system cancer	1.49e-05	0.00021	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—lymphatic system cancer	1.47e-05	0.000207	CcSEcCtD
Doxorubicin—Decreased appetite—Methotrexate—lymphatic system cancer	1.45e-05	0.000205	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.44e-05	0.000203	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—lymphatic system cancer	1.44e-05	0.000203	CcSEcCtD
Doxorubicin—Pain—Methotrexate—lymphatic system cancer	1.43e-05	0.000202	CcSEcCtD
Doxorubicin—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	1.41e-05	0.00753	CbGdCrCtD
Doxorubicin—Feeling abnormal—Methotrexate—lymphatic system cancer	1.38e-05	0.000194	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.37e-05	0.000193	CcSEcCtD
Doxorubicin—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	1.33e-05	0.00711	CbGdCrCtD
Doxorubicin—Urticaria—Methotrexate—lymphatic system cancer	1.33e-05	0.000187	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—lymphatic system cancer	1.32e-05	0.000186	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—lymphatic system cancer	1.32e-05	0.000186	CcSEcCtD
Doxorubicin—Hypersensitivity—Methotrexate—lymphatic system cancer	1.23e-05	0.000174	CcSEcCtD
Doxorubicin—Asthenia—Methotrexate—lymphatic system cancer	1.2e-05	0.000169	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—lymphatic system cancer	1.18e-05	0.000167	CcSEcCtD
Doxorubicin—Diarrhoea—Methotrexate—lymphatic system cancer	1.14e-05	0.000161	CcSEcCtD
Doxorubicin—Dizziness—Methotrexate—lymphatic system cancer	1.1e-05	0.000156	CcSEcCtD
Doxorubicin—Vomiting—Methotrexate—lymphatic system cancer	1.06e-05	0.00015	CcSEcCtD
Doxorubicin—Rash—Methotrexate—lymphatic system cancer	1.05e-05	0.000149	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—lymphatic system cancer	1.05e-05	0.000148	CcSEcCtD
Doxorubicin—Headache—Methotrexate—lymphatic system cancer	1.05e-05	0.000148	CcSEcCtD
Doxorubicin—Nausea—Methotrexate—lymphatic system cancer	9.92e-06	0.00014	CcSEcCtD
